Clinical trialNCT03326752CompletedPhase 1Interventional

Phase 1b DV281 With an Anti-PD-1 Inhibitor in NSCLC

SponsorDynavax Technologies CorporationEnrollment26Advanced Non Small Cell Lung Cancer

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This open-label, multicenter, dose-escalation and expansion trial is designed to evaluate the safety and preliminary efficacy of inhaled DV281 in combination with nivolumabfor the treatment of NSCLC and to select a recommended phase 2 dose (RP2D).

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Edward Garon, MD
University of California, Los Angeles
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Moores Uc San Diego Cancer Center
La Jolla, California, United States
Ronald Reagan University of California Los Angeles Medical Center
Santa Monica, California, United States
Allina Health, Virginia Piper Cancer Institute
Minneapolis, Minnesota, United States
Sarah Cannon Research Institute
Nashville, Tennessee, United States
Virginia Cancer Specialists
Fairfax, Virginia, United States
Seattle Cancer Care Alliance
Seattle, Washington, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Approved Anti-PD-1 InhibitorDV281

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 20 Sept 2017
Primary completion: 19 Sept 2019
Completion: 19 Sept 2019
Last update posted: 17 Jun 2020
Registered enrollment: 26
Registry id: NCT03326752

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.